Media

ASA404

Disrupting established tumor vasculature, inhibiting tumor blood flow and causing extensive tumor necrosis

The tumor vasculature is a validated target for selective cancer therapy.¹ Unlike antiangiogenic agents, which predominantly inhibit neovascularization, Tumor-Vascular Disrupting Agents (Tumor-VDAs) target the established tumor vasculature.² Tumor-VDAs cause tumor blood flow shutdown, which deprives tumors of the necessary nutrients, leading to tumor necrosis.

ASA404* is a Tumor-VDA with a unique mechanism of action that comprises direct and indirect anti-tumor activity.³ Direct tumor endothelial cell apoptosis results in a rapid reduction in tumor blood flow and increased tumor vascular permeability. In the second stage, ASA404 induces the release of tumor necrosis factor-α (TNF-α) and nitric oxide. This intratumoral vasoactive cascade results in a sustained collapse of tumor blood flow and last extensive tumor necrosis.

Synergistic activity of ASA404 and chemotherapy has been demonstrated in preclinical models.^4,5 There is a clear rationale for combining ASA404 with standard chemotherapy.^4,5 In a randomized Phase II study, ASA404, in combination with paclitaxel/carboplatin, was well tolerated and demonstrated a survival advantage in first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (NSCLC).^6,7

ASA404 is currently being investigated in a Phase III development program in first- and second-line NSCLC. It is also being evaluated in other solid tumors.

*ASA404 (formerly known as AS1404) is licensed from Antisoma, U.K.

1. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10:415-427.
2. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5:423-435.
3. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003;4:141-148.
4. Kelland LR. Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev. 2005;1:1-9.
5. Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol. 2003;51:43-52.
6. van Powel J, Reck M, McKeage M, AS1404-201 Study Group Investigators. Update on survival in a phase Ib/II study of DMXAA (AS1404) combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). Presented at AACR-NCI-EORTC. November 2006; Prague, Czech Republic.
7. McKeage M, von Pawel J, ASA404-201 Study Group Investigators. Phase II study of DMXAA (ASA404) 1800mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer. Presented at World Lung Cancer Conference. September 2007; Seoul, South Korea.